• HOME
  • ABOUT MORSE
    • About Us
    • The Team
      • Arvind Mani
      • Sherry O’Quinn
      • Brad Alyward
      • Anita Gadhok
      • Sophia Gran-Ruaz
      • Avery Hughes
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
  • SERVICES
    • Our Services
    • Reimbursement Strategy
    • Negotiation Strategy
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
  • HOME
  • ABOUT MORSE
    • About Us
    • The Team
      • Arvind Mani
      • Sherry O’Quinn
      • Brad Alyward
      • Anita Gadhok
      • Sophia Gran-Ruaz
      • Avery Hughes
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
  • SERVICES
    • Our Services
    • Reimbursement Strategy
    • Negotiation Strategy
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

pCPA Update as of December 31, 2017

January 16, 2018
-
Market Access News
-
Posted by MORSE Team - 3 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update

 

The December 31, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are:

  • Five new drug products have initiated pCPA negotiations, for a total of 36 active negotiations;
  • Eight negotiations have been completed/closed, for a total of 196 joint completed/closed negotiations; and
  • One new drug product was added to the “No pCPA Negotiations” list, for a total of 57 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level.

In addition to the information above, MORSE Consulting is tracking the number of products reviewed by CADTH that have yet to initiate negotiations with the pCPA – which we refer to as “under pCPA Consideration”. The latest update since November 30, 2017 is:

  • Two new drug products have received recent CDEC or pERC recommendations, for a total of approximately 20 products under pCPA Consideration

Please see below for more details.

Negotiation Initiation

Five new drug products have initiated pCPA negotiations since the last update, for a total of 36 active negotiations

Brand Name Generic Name Manufacturer Indication Recommendation/
Notification to Implement Date
Time to Negotiation*
(days)
Blincyto blinatumomab Amgen Canada Adult Acute Lymphoblastic Leukemia (ALL) September 18. 2017 88 days
Blincyto blinatumomab Amgen Canada Pediatric Acute Lymphoblastic Leukemia September 8, 2017 98 days
Caprelsa** vandetanib Sanofi Genzyme Medullary Thyroid Cancer April 17, 2017 242 days
Lancora Ivabradine Servier Canada Inc. Heart failure, NYHA class II or III May 24, 2017 205 days
Ocaliva Obeticholic acid Intercept Pharma Canada Inc. Primary biliary cholangitis July 25, 2017 143 days

*Approximation: Negotiation initiation date assumed to be mid-month for the purposes of the calculation

** Note: This is the second negotiation for Caprelsa, the first was closed in August 2017

 

Negotiations Completed

  • Eight negotiations have been completed/closed since the last update, for a total of 196 joint completed/closed negotiations.
    • Eight negotiations were completed:
Brand Name Generic Name Manufacturer Indication Negotiation Initiation Duration *
(days)
Cosentyx secukinumab Novartis Pharmaceuticals Canada Inc, Psoriatic Arthritis April, 2017 244 days
Cosentyx secukinumab Novartis Pharmaceuticals Canada Inc, Ankylosing Spondylitis April, 2017 244 days
Ibrance palbociclib Pfizer Canada Inc. Advanced Breast Cancer May, 2017 214 days
Kyprolis carfilzomib Amgen Canada Inc. Multiple Myeloma October, 2016 426 days
Kyprolis carfilzomib Amgen Canada Inc. Multiple Myeloma (relapsed) June, 2017 183 days
Ravicti Glycerol phenylbutyrate Horizon Therapeutics Canada/Horizon Pharma Ireland Ltd Urea cycle disorders April, 2017 244 days
Taltz Ixekizumab Eli Lilly Canada Inc. Moderate to severe plaque psoriasis May, 2017 214 days
Uptravi Selexipag Actelion Pharmaceuticals Canada Inc. Pulmonary arterial hypertension April, 2017 244 days
  • No negotiations were closed.

No pCPA Negotiation

  • One new drug product was added to the “No pCPA Negotiations” list, for a total of 57 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level
Brand Name Generic Name Manufacturer Indication Recommendation/
Notification to Implement Date
CADTH Recommendation Time to decision*
(days)
Rituxan Rituximab Hoffman-La Roche Limited Acute lymphoblastic leukemia September 18, 2017 Does not Recommend 88 days

*Approximation: decision date assumed to be mid-month for the purposes of the calculation

Based on information collected by MORSE Consulting:

  • Two new drug products received a CDEC or pERC recommendation or notification to implement since the last update, for a total of approximately 20 products under pCPA Consideration.
Brand Name Generic Name Manufacturer Indication Final Recommendation/Notification to Implement
Opdivo & Yervoy in combo Nivolumab & ipilimumab Bristol Myers Squibb Canada Metastatic Melanoma Conditional Reimbursement
Spinraza Nusinersen Biogen Canada Inc. Spinal Muscular Atrophy Reimburse with clinical criteria and/or conditions

 

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Google+ (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
Tags
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
← PREVIOUS POST
pCPA: 2017 Year in Review
NEXT POST →
Brad Alyward Joins MORSE Consulting as Principal Consultant
Contact Us
MORSE Consulting Inc.
Toronto | Ottawa
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:
Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering pharmaceutical market access signals to create reimbursement success.
© 2019 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
pCPA Update as of December 31, 2017
css.php